No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 37 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Cancer in My Community: The 3 Ways People Access Cancer Care... February 2, 2023 Five Questions With…Sharon. May 12, 2022 The Potential of AI to Improve Cancer Care is Only Going... October 16, 2023 Using Technology to Find Cancers Early and Exercise Improves Sexual Health... July 31, 2023 Load more HOT NEWS Women and girls in science: We won’t stop pushing for progress Man Offers Free Lawn Mowing Service To Elderly And Veterans Gift Giving During a Pandemic European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025
